Integral University Researcher Dr. Snober S. Mir nominated for SERB-STAR (Science and Technology Award for Research)

Dr. Snober Shabnam Mir, has been nominated for the SERB-STAR (Science and Technology Award for Research) Award as the project entitled "Role of p53 aggregation in dysregulation of autophagy: Implications for tumorigenesis and targeted therapy" under YSS-LS Scheme, successfully completed by her, was evaluated by the review

committee and rated "Excellent". SERB-STAR (Science and Technology Award for Research) is a prestigious award instituted by SERB to recognize and reward outstanding Principal Investigators (PIs) SERB Projects. The nominee should have of completed SERB project under EMR/CRG, YSS, ECRA or EMEQ Schemes in previous three financial years with "Excellent" grading. Only the PIs of such projects are eligible for these nominations. Dr. Mir spearheads the laboratory of Molecular Cell Biology



wherein her team endeavours to identify the modulators of protein quality control machinery and their role in disease biology, specifically in cancer and neurodegeneration. Studying the biology of protein p53, which is a pivotal tumour suppressor protein, Dr. Mir's group has successfully provided evidence that the aggregation of p53 is an important etiological factor towards tumour formation. The group has been successful in establishing a model of p53 aggregation which is a significant contribution in the field as it will open newer avenues towards understanding the activation of oncogenic pathways. She has successfully completed two research projects funded by DBT and SERB as a Principal Investigator. She has also trained DAAD RISE (Research Internship in Science and Engineering) interns in her laboratory on short training projects funded by DAAD-RISE Worldwide (Germany). One project was approved under her mentorship in the SERB-NPDF programme. Her work has been published in 54 peer reviewed international journals most notably Molecular Cell Biology ,Frontiers in Oncology, Life Sciences , Glycobiology , Cancer Medicine, PLoS ONE, Molecular Cancer Research, Cellular Signalling, Biochemical Biophysical Research Communications etc.